Senior Management Team

Become a leading global bio pharmaceutical company
for the development of novel drugs


Dr. Shui On LEUNG

Founder, Chairman of our Board, Executive Director, Chief Executive Officer


Dr. Leung was appointed as a Director and the chairman of our Board in April 2001 and subsequently appointed as our chief executive officer in January 2003 and subsequently designated as an executive Director in June 2019. Dr. Leung is primarily responsible for formulating overall strategic directions, overseeing scientific and clinical R&D activities and managing overall operations of our Group.
Dr. Leung has nearly 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. Dr. Leung has been a member of the first session of Biotech Advisory Panel of the Stock Exchange since April 2018. He has also been an adjunct professor of the Hong Kong University of Science and Technology since September 2018. From 2011 to 2014, Dr. Leung was an adjunct professor of Fudan University, China (復旦大學). Dr. Leung was also an adjunct professor of the Army Medical University (中國人民解放軍陸軍軍醫大學, formerly the Third Military Medical University (中國人民解放軍第三軍醫大學)), China and the Air Force Medical University (中國人民解放軍空軍軍醫大學), formerly known as the Fourth Military Medical University (中國人民解放軍第四軍醫大學)). Prior to joining our Company, Dr. Leung served as the managing director of the Hong Kong Institute of Biotechnology Limited, which is currently a biotechnology R&D arm of the Chinese University of Hong Kong, from September 2000 to December 2002. Dr. Leung was an adjunct professor of the Chinese University of Hong Kong from February 2001 to January 2004. From May 1991 to in or around August 2000, he held several positions in Immunomedics, Inc. (“Immunomedics”), a U.S. leading antibody-drug conjugate company, including an associate director of the molecular biology department and an executive director of the biology research department. During his term with Immunomedics, Dr. Leung was awarded grants by the U.S. Department of Health and Human Services multiple times for his research programs, including “Engineering a Unique Conjugation Site on AB Light Chain” and “A Humanised Antibody for Breast Cancer Treatment”. In October 1996, Dr. Leung was appointed as an adjunct assistant member of the Centre for Molecular Medicine & Immunology at Garden State Cancer Centre. Dr. Leung was also engaged in postdoctoral research at Yale University, U.S.A. from July 1990 to June 1992. Dr. Leung was a director of Novelmab from September 2011 to July 2018, our then subsidiary in Hong Kong, which was dissolved by deregistration on 8 May 2019 under section 751 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong).
Dr. Leung obtained his bachelor’s and master’s degrees in biochemistry from the Chinese University of Hong Kong in December 1984 and October 1986, respectively. He earned his Ph.D. in molecular biology from the University of Oxford in Oxford, England in May 1990.

Mr. Jing QIANG

Executive Director, President


Mr. QiaMr. Qiang has served as the president of the Company since March 2018 and was appointed as an Executive Director on 23 December 2019. Mr. Qiang is primarily responsible for strategic planning and investments.
Mr. Qiang has over nine years of experience in the field of medicine and healthcare related research and investment. Mr. Qiang has served as the chairman of Suzhou Sinovent Pharmaceutical Technology Co., Ltd. (蘇州信諾維醫藥科技有限公司). Prior to that, Mr. Qiang worked at China International Capital Corporation Limited (Stock Exchange: 3908) from July 2010 to March 2018, where he held the position of managing director when he left. During his term with China International Capital Corporation Limited, Mr. Qiang won Asiamoney’s best research coverage in healthcare in 2014 to 2017 and was ranked top three in healthcare by the 2015-2017 China Research Team of Institutional Investor.
[Mr. Qiang obtained his bachelor’s degree in pharmacy from Shanghai Jiao Tong University, China (上海交通大學) in July 2005 and his master’s degree in finance from Fudan University, China (復旦大學) in June 2010. Mr. Qiang completed the High Impact Cancer Research (HI-CR) Program of Harvard Medical School in the United States in 2019.
Mr. Qiang was qualified as a Chartered Financial Analyst by the CFA Institute in September 2011 and as a Financial Risk Manager by the Global Association of Risk Professionals in April 2009.

Mr. Jianping HUA

Chief Financial Officer


Mr. Hua has served as the chief financial officer of our Company since January 2019 and is primarily responsible for overall financial operations, financing and investment activities of our Group.
Mr. Hua has more than 14 years of experience in financial and investment matters. Prior to joining our Group, Mr. Hua served as a vice chief financial officer, member of the executive board of the president, vice president of medical technology management committee and held a number of positions comprising vice director of financial audit, director of financial audit and deputy general manager of the finance department of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (上海復星醫藥(集團)股份有限公司, Shanghai Stock Exchange: 600196 and Stock Exchange: 2196) from February 2011 to January 2019. He also served as an executive director of Sisram Medical Ltd (Stock Exchange: 1696), from March 2018 to January 2019, and as the chief financial officer from February 2014 to January 2019. From August 2005 to February 2011, Mr. Hua served as a manager in the assurance department at PricewaterhouseCoopers Zhong Tian Certified Public Accountants Co., Ltd. (普華永道中天會計師事務所有限公司). Mr. Hua obtained his bachelor’s degree in English from Shanghai University, China (上海大學) in July 2005.

Mr. Gang CHEN

Chief Medical Officer


Mr. Chen has served as the chief medical officer of our Company since July 2018 and is primarily responsible for overall management of our clinical trials and drug-related regulatory affairs.
Mr. Chen has approximately 20 years of experience in the fields of clinical development and medical science in various multinational pharmaceutical companies and leading domestic innovative pharmaceutical companies. Prior to joining our Group, Mr. Chen served as a senior medical director of Shanghai Hengrui Pharmaceutical Co., Ltd. (上海恒瑞醫藥有限公司), a subsidiary of Jiangsu Hengrui Medicine Co., Ltd. (江蘇恒瑞醫藥股份有限公司, Shanghai Stock Exchange: 600276), in charge of overseeing clinical development program of innovative oncology drugs (including part of overseas clinical studies), from February 2017 to June 2018. From October 2014 to February 2017, Mr. Chen served as Senior Medical Director of Eddingpharm Co., Ltd., Shanghai Branch (億騰藥業有限公司上海分公司), responsible for clinical development of innovative oncology medicines for the company. From June 2007 to October 2014, Mr. Chen held several key positions, including principal physician, deputy director of medical science and head of the medical science team, at AstraZeneca Investment (China) Co., Ltd. (阿斯利康投資(中國)有限公司), a subsidiary of AstraZeneca plc (London Stock Exchange: AZN), in charge of clinical research, clinical development and medical affairs of innovative drugs and prescription drugs. From June 2002 to June 2007, Mr. Chen served as Senior Medical Manager at Xi’an Janssen Pharmaceutical Ltd. (西安楊森製藥有限公司), a subsidiary of Johnson & Johnson (New York Stock Exchange: JNJ), in charge of clinical research, medical support of innovative drugs and prescription drugs.
Mr. Chen obtained his bachelor’s degree of clinical medicine from the School of Medicine of Shanghai Jiao Tong University (上海交通大學醫學院) (formerly known as Shanghai Second Medical University (上海第二醫科大學)) in July 1993. He received his master’s degree in business administration from the John Molson School of Business, Concordia University in Montreal, Canada in May 2000.

Dr. Ming Hon YAU

Director (Downstream Process Development)


Dr. Yau joined our Company in January 2012 as a research project manager (R&D), subsequently as an associate director (R&D) of our Company from January 2015 to March 2019 and has served as a managing director (downstream process) of our Company since April 2019. Dr. Yau is primarily responsible for supervising downstream purification process development, overseeing manufacturing operations of antibody products, establishing associated GMP system, and supervising operation compliance and planning of Suzhou production base.
Dr. Yau has over 13 years of experience in the fields of research, development and manufacturing of biological products. From July 2011 to December 2011, he served as an assistant manager of Nano and Advanced Materials Institute Limited (納米及先進材料研發院有限公司). From February 2008 to June 2011, Dr. Yau worked as an R&D assistant manager and subsequently as a manufacturing project manager at New A Innovation Limited (新意康生物科技有限公司), a company in Hong Kong focusing on life science and animal health, responsible for overseeing all upstream process development, establishing pilot production sites in different locations in China, establishing and operating a GMP-compliance manufacturing facility at New Zealand and technology transfer. From April 2006 to April 2008, Dr. Yau served as a full-time postdoctoral fellow in the Li Ka Shing Faculty of Medicine of the University of Hong Kong, focusing on monoclonal antibody production and immunoassay development to provide tools for the early diagnosis of diabetes and cardiovascular diseases.
Dr. Yau received his bachelor’s degree, master’s degree and Ph.D. in biochemistry from the Chinese University of Hong Kong in December 2000, December 2002 and December 2005, respectively. Dr. Yau was registered as a registered quality manager with the Hong Kong Quality Management Association in September 2012.

Dr. Kwan Yin SIU

Associate Director (Manufacturing/Upstream processing group)


Dr. Siu joined our Company in November 2011 as a research scientist, subsequently as principal senior scientist (bioprocess) from January 2015 to March 2019, and has served as an associate director (manufacturing/ upstream processing group) of our Company since April 2019. Dr. Siu is primarily responsible for supervising upstream production and research process for culture media preparation, cell culture and bioreactor perations.
Dr. Siu has over 10 years of experience in the area of R&D of cell culture and related process. Prior to joining our Group, Dr. Siu served as a stem cell scientist at Asia Pacific Stem Cell Science Limited (亞太幹細胞科研中心有限公司), a cord blood storage services company in Hong Kong, from June 2009 to September 2011, responsible for stem cell research. From January 2009 to May 2009, Dr. Siu served as an assistant engineer at Sundart (M&E) Limited (承達機電工程有限公司). Dr. Siu received his bachelor’s degree in science, master’s degree and Ph.D. in molecular genetics from the University of Hong Kong in November 2001, December 2004 and November 2008, respectively.

Dr. Ka Wa Benny CHEUNG

Principal Senior Scientist


Dr. Cheung joined our Company in January 2010 as a research scientist and has served as a principal senior scientist of our Company since January 2015. Dr. Cheung is primarily responsible for managing R&D laboratory in Hong Kong.
Dr. Cheung has over 12 years of experience in the area of R&D of drugs. Prior to joining our Group, Dr. Cheung served as a technical officer and subsequently as a senior technical officer at the Department of Paediatrics and Adolescent Medicine at the University of Hong Kong from September 2007 to January 2010, respectively, in charge of overseeing R&D projects.
Dr. Cheung obtained his bachelor’s degree in biochemistry, master’s degree in immunology and Ph.D. in immunology from the University of Hong Kong in November 2001, December 2004 and November 2008, respectively.